Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Invested Capital (2018 - 2025)

Ultragenyx Pharmaceutical has reported Return on Invested Capital over the past 8 years, most recently at 0.15% for Q4 2025.

  • Quarterly Return on Invested Capital rose 17.0% to 0.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.15% through Dec 2025, up 17.0% year-over-year, with the annual reading at 0.06% for FY2025, 4.0% down from the prior year.
  • Return on Invested Capital was 0.15% for Q4 2025 at Ultragenyx Pharmaceutical, up from 0.07% in the prior quarter.
  • Over five years, Return on Invested Capital peaked at 0.15% in Q4 2025 and troughed at 0.07% in Q3 2023.
  • The 5-year median for Return on Invested Capital is 0.02% (2022), against an average of 0.01%.
  • Year-over-year, Return on Invested Capital dropped -6bps in 2023 and then grew 17bps in 2025.
  • A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2021, then crashed by -603bps to 0.02% in 2022, then plummeted by -363bps to 0.07% in 2023, then skyrocketed by 76bps to 0.02% in 2024, then skyrocketed by 949bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Invested Capital are 0.15% (Q4 2025), 0.07% (Q3 2025), and 0.03% (Q2 2025).